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Abstract
Green tea and black tea originate from the leaves of Camellia Sinensis plant and
contain antioxidants known to possess antiviral properties, including anti-HSV (Herpes
Simplex Virus). There is no cure for the diseases caused by HSV infections. While there
is a rising concern over the increase in resistant HSV strains, new effective agents for
prevention are in critical need to be developed. Green tea’s polyphenol epigallocatechin
gallate (EGCG), and its modification palmitoyl-EGCG (p-EGCG), along with black tea
theaflavins TF1, TF2, TF3 have been used to study their antiviral effect against HSV type
1 (HSV-1) and HSV type 2 (HSV-2). These compounds with concentrations of 0, 6.25,
12.5, 25, 50, and 75 μM were used on Vero and A549 cells to determine cell viability and
cytotoxicity, and were shown to have no significant toxic effect in either one of the cell
lines. Plaque assay, flow cytometric assay, fluorescence microscopy, polymerase chain
reaction (PCR), and quantitative real-time PCR (qPCR) all demonstrated that EGCG and
p-EGCG are effective in inhibiting HSV-1, with p-EGCG being the most efficient.
Furthermore, binding assay suggests that p-EGCG is able to block viral glycoprotein(s)
and efficiently inhibit the binding of HSV-1 to host receptors. Similar results were seen
when cells were infected with HSV-2; plaque assay, flow cytometric assay, and
fluorescence microscopy showed that p-EGCG is very effective in inhibiting HSV-2 (>
99%).
Black tea theaflavins were also efficient in preventing HSV-1 and HSV-2
infection in both cell lines. Plaque assay, flow cytometric assay, fluorescence
microscopy, qPCR and scanning electron microscopy (SEM) demonstrated that all three

x

theaflavins have strong antiviral capabilities, with TF3 being the most efficient. Binding
and penetration assays also suggest that theaflavins are able to block viral binding of
HSV to host cell receptors.
Overall, results indicated that all of the compounds used are effective anti- HSV-1
and HSV-2 agents, with p-EGCG being the most efficient from green tea and TF3 being
the most efficient from black tea. Several experimental approaches used here showed
that a concentration of 50 μM and above of p-EGCG and TF3 were sufficient to inhibit >
99% of HSV-1 and HSV-2 virions in both of the cell lines used. Finally, binding and
penetration assays suggest that the antiviral activity of p-EGCG and TF3 may be through
blocking the virus’ ability to bind/penetrate host cells and in turn prevent infection. Thus,
green tea polyphenols and black tea theaflavins may serve as novel antiviral treatments
that can substitute or complement current anti-HSV medications.
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Introduction
Herpes Simplex Viruses Classification
Herpes simplex viruses (HSVs) are DNA viruses that belong to the Herpesviridae
family,

and

are

part

of

three

subfamilies

known

as

Alphaherpesviridae,

Betaherpesviridae, and Gammaherpesviridae. Within these subfamilies, there are eight
viruses known to be human pathogens including HSV-1, HSV-2, Varicella zoster virus,
cytomegalovirus, Epstein-Barr virus (EBV), human herpesvirus 6, human herpesvirus 7
and kaposi’s sarcoma (Kelly et al., 2009). The two serotypes (HSV-1 and HSV-2) that
compose the HSV Herpesviridae family are further classified into the subfamily
Alphaherpesviridae and Simplexvirus genus. While the majority of herpesviruses are able
to infect different animal species, HSV-1 and HSV-2 are host specific (Akhtar and
Shukla, 2009).

Herpes Simplex Viruses Prevalence
HSV-1 and HSV-2 are among the most common transmissible diseases in human.
It is estimated that 45%-98% of the world’s population are infected with HSV-1 and 7%
are infected with HSV-2 (Fatahzadeh and Schwartz, 2007a.) Every year, over half a
million people acquire herpes infections in the U.S, while first time HSV infection cases
continue to rise annually (CDC, 2013; Stanberry, 2006). In the United States (US) alone,
between 1999 and 2004, 57.7% of examined individuals aged 14 to 49 were seropositive
for HSV-1 and 17% were seropositive for HSV-2 (Bradley et al., 2014; Xu et al., 2006).
The same held true from 2005-2010, in which 16.2%, or one out of six Americans, aged

1

14 to 49 were diagnosed with HSV-2 infection (CDC, 2013). While the overall
seroprevalence of HSV-1 has decreased by 23% in 14-19 year olds, and by 9% in 20-29
year olds while staying the same in 30-39 and 40-49 year olds, it has not changed
significantly for HSV-2 in any age group. In fact, HSV-2 seroprevalence has increased
from 13.4% to 15.7% since 1976, with an estimated 23 million new infections each year
(Looker et al., 2008).
The incidence of HSV infections is dependent upon several factors, including age,
race, socioeconomic status and geographic distribution. Worldwide, 70-80% of adults
belonging to lower socioeconomic classes are infected with HSV-1, compared to only 4060% of adults in better socioeconomic conditions. In less privileged areas of the U.S,
33% of children are affected with HSV-1 by age 5, while only 20% of children will test
HSV positive by age 5 in more privileged areas. Furthermore, in the U.S alone 35% of
African American 5-year old children test positive for HSV-1 serum antibody compared
to 18% of white 5-year old children. In addition, African American women have been
seen to have a greater incidence of HSV-2 (48%) worldwide compared to men
(Fatahzadeh and Schwartz, 2007b).

Herpes Simplex Genome and Structure
Herpes virions are approximately 200 nm in diameter (Fatahzadeh and Schwartz,
2007b). The structure of HSV is comprised of a DNA core, capsid, tegument and an
envelope. The viral icosahedral capsid encases the linear double stranded (ds) DNA,
which in turn is surrounded by a layer of tegument proteins. Surrounding the tegument
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layer is the viral envelope containing many glycoproteins (Kelly et al., 2009) (Fig. 1).
The genomes of HSV-1 and HSV-2 are closely related, (82% shared amino acid
sequence) with HSV-1 comprising a 152,261 bp genomic DNA sequence, and HSV-2 a
154,746 bp genomic DNA sequence (Akhtar and Shukla, 2009; Dolan et al., 1998).
Although they contain similar DNA composition, HSV-1 and HSV-2 are considered to be
antigenically distinct, mainly due to differences in their envelope proteins (Fatahzadeh
and Schwartz, 2007b). HSV-2 also has 2.1% more G-C rich content than HSV-1 in its
DNA (Dolan et al., 1998).
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Figure 1: General structure of HSV virion showing the viral envelope, nucleocapsid, tegument
protein layer, and glycoprotein spikes (gB-gN).

Image citation notice: all images included in this dissertation are generated by the author
unless otherwise cited.
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Herpes Simplex Virus 1 &2 Life cycle
The life cycle of HSV-1 and HSV-2 are fairly similar. The virus infects epithelial
cells at the first sight of infection, and takes over the host cell cytoplasm and nucleus for
replication (Shukla and Spear, 2001). The viral envelope is composed of 10-12
glycoproteins including glycoprotein B (gB), gC, gD, gH, gL, gM, gE, gI, and gK. Five
of these glycoproteins (gB, gC, gD, gH and gL) are involved in host cell receptor
identification, binding and fusion, and thus occupy a larger area of the envelope (Akhtar
and Shukla, 2009; Garner, 2003). The first contact with the host cell by HSV is through
binding of gB and or gC with heparan sulfate chains on cell surface proteoglycans
(HSPG) (Akhtar & Shukla, 2009). HSPG are polymers of disaccharides that contain a
glucosamine and a glucuronic acid residue and serve as the first point of virus recognition
to the host cells (Akhtar and Shukla, 2009). Upon binding of gB to HSPG, gD will also
play a crucial role in receptor-ligand interaction by recognizing and binding to the proper
receptor upon contact. There are three different classes of receptors to which gD may
bind. These include herpesvirus entry mediator (HVEM), a member of the tumor
necrosis/nerve growth factor, nectin-1 and nectin-2, and modified heparan sulfate through
glucosaminyl 3-O-sulfotransferases (3-O HS). HSV-1 and HSV-2 have different
preferences for receptor binding; while both virus types use HVEM, nectin-1 and nectin2, the 3-O HS is only used by HSV-1 (Akhtar and Shukla, 2009). It is still unknown
whether the ability to bind to 3-O HS has a direct effect on tissue preference, which may
be directly linked to differences between the two serotypes. While there are different
receptors for gD HSV to bind, they are also often found in different cell types. HSPG has
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been found in several cell types, but nectin-1 and nectin-2 is found at junctions of
epithelial cells and synaptic junctions of neurons. HVEM has been mainly seen in T
lymphocytes and trabecular meshwork cells (Akhtar and Shukla, 2009; Garner, 2003).
Viral entry occurs through the fusion of the viral envelope with the host cell
membrane by the action of gB, gD, gH and gL (Akhtar & Shukla, 2009). gD first
recognizes and binds to a host cell receptor, causing a conformational change in gD, and
in turn, allowing gB, gC and the heterodimer gHgL to aid in viral fusion and entry. While
gC is needed for binding, it is not essential for viral entry. In addition, experiments in
which gB or gH, gL were deleted, it was observed that the virus was able to bind but lost
its ability to penetrate host cells (Forrester et al., 1992; Garner, 2003).
Upon binding, the fusion complex composed of gB, gD, gH and gL, causes a
fusion pore to form, which allows the host cell contents to mix with the viral
nucleocapsid and the tegument proteins. Viral fusion with the host cell membrane is
triggered by two different pathways, which include endocytosis, and or multiple receptorligand binding and fusion of the host cell plasma membrane with the viral envelope, with
the latter being the most preferred way (Subramanian and Geraghty, 2007). Once inside,
the viral nucleocapsid and tegument proteins are transported to the host cell cytoplasm
through a microtubule and dynein dependent mechanism. Then, the viral nucleocapsid
travels to the nuclear membrane of the cell, and the viral DNA is transferred to the
nucleoplasm for replication (Akhtar and Shukla, 2009; Garner, 2003; Kelly et al., 2009).
Upon reaching the nucleoplasm, viruses will activate viral transcription, translation, DNA
replication, and assembly of new virions. Transcription of viral DNA occurs through a
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series of separate steps, including immediate early (IE), early (E), and late (L) genes.
There are 5 immediate early genes, which code for transcription factors, and are
responsible for regulating HSV gene expression. The 12 E genes are greatly involved in
viral genome replication, such as the pUL23, thymidine kinase involved in nucleic acid
metabolism. The 56 L genes are involved in the formation of the viral structural proteins,
which include the capsid, tegument and envelope proteins. Upon synthesizing new
virions in the host cell nucleus, the virus acquires tegument proteins and a double
envelope (Bloom et al., 2010; Nakabayashi and Sasaki, 2009; Watanabe, 2010). The
newly synthesized virions are then transferred back to the periphery of the cell by
anterograde transport, where they will exit and will be free to infect new or adjacent cells
(cell-to-cell spread) (Fig. 2). Cell-to-cell spread is achieved through the help of gE and gI
in most cells. Studies have also shown that in corneal and trigeminal ganglia cells, gK
also plays an important role needed for effective cell-to-cell spread (David et al., 2008).
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Figure 2: General HSV life cycle. HSV enters the host cell through the fusion of the viral
envelope with the host cell membrane. Upon entering, the viral nucleocapsid and tegument
proteins are transported to the host cell cytoplasm. Next, the viral nucleocapsid travels to the
nuclear membrane of the cell, and the viral DNA is transferred to the nucleoplasm for replication.
Then, viral transcription, translation, DNA replication, and packaging of new virions are
activated. The newly synthesized virions are then transferred back to the periphery of the cell by
anterograde transport, where they will exit to infect new or adjacent cells.
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HSV is able to establish latent infections by infecting trigeminal (HSV-1) and
lumbosacral dorsal root (HSV-2) ganglia (Akhtar and Shukla, 2009; Fatahzadeh and
Schwartz, 2007b) (Fig. 3, 4). Viral particles will travel from the initial site of infection in
a retrograde manner to the sensory ganglia. When this occurs, the virus genome will
remain dormant within the host cell nucleus and will express only a limited number of
viral proteins. During the latent stage of viral infection, HSV genome will circularize and
the virus will produce a transcript known as Latency-Associated Transcript (LAT). In
order to effectively establish the latent infection, LAT is spliced, producing a 2 kbp RNA
intron. The splicing of LAT activates histone modification enzymes, which in turn will
interact with the viral DNA and suppress the expression of lytic genes (Kang et al.,
2003). This process allows the virus to survive for the lifetime of the infected person.
Viral lytic reactivation may occur any time during a person’s life. While it is still difficult
to pinpoint an exact reason for the reactivation, environmental factors such as fatigue,
stress, cold, heat, nerve damage, and UV light have all been associated with it
(Fatahzadeh and Schwartz, 2007b).
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Trigerminal ganglion- Site of viral latency

Active site of HSV infection

Figure 3: Site of HSV-1 latent infection, the trigeminal ganglion.

Sacral ganglion

Figure 4: Site of HSV-2 latent infection, the lumbodorsal root ganglion
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Herpes Simplex Viruses Transmission and Diagnoses
HSV infection affects the skin and mucous membranes of the body (Whitley and
Roizman, 2001). HSV-1 has been associated with non-genital infections, usually
affecting regions of the oropharyngeal mucosa. HSV-1 is primarily transmitted through
oral secretions and is known to cause lesions in the mouth as well as herpes keratitis, an
infection of the eye. Herpes keratitis is the main cause of corneal blindness in the U.S
(Fatahzadeh and Schwartz, 2007b). HSV-2 is primarily transmitted through sexual
contact and is associated with infection of the genital mucosa. However, both viruses are
capable of infecting and causing lesions in both areas and are known to cause long-term
life threatening conditions in patients, especially in immunocompromised hosts. HSV has
also been linked to encephalitis in both newborns and adults. Seventy percent of patients
with encephalitis suffer major neurological conditions with high mortality rates
(Fatahzadeh and Schwartz, 2007b).
Those who are infected, have a high risk of transmitting the disease (viral
shedding) even when no symptoms are present (Mertz, 2008). Asymptomatic viral
shedding can be present in blisters, saliva, patient tears, and vaginal mucosa. Neonatal
herpes is also a devastating condition that often leads to death. It is passed to infants
during vaginal birth through direct exposure to the mother’s secretions. Twenty percent
of pregnant women are HSV-2 seropositive, but only 5% have showed symptoms, and
thus may unknowingly pass the virus to the baby (Fatahzadeh and Schwartz, 2007b).
When symptoms are apparent, diagnoses of HSV may be done through direct
observation of lesions. Unfortunately, most of the HSV-2 cases are misdiagnosed, and
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laboratory tests are needed in order to obtain a definite diagnosis. The tests currently
conducted range from viral isolation in culture, to direct fluorescent antibody studies,
tissue biopsy and PCR for viral DNA detection (Fatahzadeh and Schwartz, 2007b).

Herpes Simplex Viruses and HIV-1
HSV-2 has been shown to increase the risk of acquiring HIV-1 by 2-3 folds and
the risk of transmitting HIV-1 by 4 folds, posing a major public health challenge(Bradley
et al., 2014). Since the patient infected with HSV may suffer with frequent lesions, these
may serve as easy gateway entry for HIV-1 (Barnabas et al., 2011; Cohen et al., 2015).
Studies have also shown that coinfection of HSV and HIV-1 might accelerate HIV-1
progression (Van de Perre et al., 2008). There is a direct link between the levels of HSV
and HIV-1 in patients that are coinfected with both viruses, and that are taking anti-HSV
medication. As the levels of HSV-2 decrease, the plasma HIV-1 RNA concentrations also
decrease, suggesting a direct relation between the two viruses (Van de Perre et al., 2008).

Herpes Simplex Viruses Management and Antiviral Agents
The psychosocial impact of HSV infection on patients is often immeasurable.
Those suffering with recurrent conditions often feel depressed, lonely and ashamed.
Education has been shown to be the most effective way of preventing those infected from
transmitting the disease. When the population is educated on appropriate preventive
measures such as wearing condoms, and or obtaining the correct topical, oral, or
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intravenous antiviral therapy, viral shedding is reduced, and the likelihood of
transmission decreases (Fatahzadeh and Schwartz, 2007b; Stanberry, 2006).
Current topical cream against HSV includes docosanol 10% cream (Abreva,
Baush & Lomb, Tampa, Fla). It contains a 22-carbon alcohol that works by blocking the
binding step of the viral glycoproteins to the epithelial host cell receptors. In turn, the
virus cannot enter cells and infection is prevented. Current oral medications include
acyclovir (Zovirax, Glaxo SmithKline, Research Triangle Park, NC), valacyclovir
(Valtrex, Glaxo SmithKline, Research Triangle Park, NC), penciclovir (Denavir, Novaris
Pharma GmbH, Wehr, Germany), and famiciclovir (Famvir, Novartis Pharmaceuticals
Corporation, East Hanover, NJ), with acyclovir being the most common form of
treatment (Brady and Bernstein, 2004; Snoeck, 2000).
These drugs are administered orally for 7-10 days and work by targeting the HSV
viral polymerase, while shutting down viral DNA replication. They are inactive in their
natural form, but become biologically active upon being sequentially phosphorylated by
both the virus thymidine kinase (TK) and host cell kinases. For instance, in acyclovir, the
viral thymidine kinase phosphorylates acyclovir and then the host cell kinase will further
phosphorylate it, ensuing an active acyclovir triphosphate. Once active, it will inhibit the
viral DNA polymerase causing a halt in viral DNA elongation. Unfortunately, the virus
has learned to overcome this inhibition by altering its DNA polymerase and or its
thymidine kinase. In such manner, it becomes resistant to acyclovir and is able to
continue its normal life cycle unaffected. In addition, acyclovir has been shown to
contain low bioavailability and short-half life in the blood of patients. Thus, numerous
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doses need to be administered in order to efficiently inhibit viral replication. Furthermore,
the cost of acyclovir can become increasingly burdensome for patients who need to take
it frequently (Bacon et al., 2003; Brady and Bernstein, 2004; Piret and Boivin, 2011;
Snoeck, 2000).
Famiciclovir has been shown to be more efficacious in obtaining higher
bioavailability and a greater short-half life compared to acyclovir, which enables the
patient to administer it with less frequency. Penciclovir also works by competing with the
DNA polymerase and in turn, blocks DNA viral synthesis. It also has a longer half-life
and higher bioavailability compared to acyclovir, but is less efficient in inhibiting the
viral DNA polymerase. Furthermore, valaciclovir has been shown to contain five times
better bioavailability compared to acyclovir, and in turn can also be administered less
frequently (Brady and Bernstein, 2004; Snoeck, 2000).
Drugs that have different modes of action have also been used in place of acyclic
guanosine analogues, when resistant strains are observed. Cidofovir is an acyclic
nucleoside 5’-monophosphate that targets the viral DNA polymerase upon being
phosphorylated by the host cell kinase. Since it is not dependent on the viral thymidine
kinase, it is able to overcome that possible resistance. Unfortunately, resistant strains
containing mutations on the DNA polymerase gene instead have been seen (Brady and
Bernstein, 2004; Piret and Boivin, 2011; Snoeck, 2000).
Foscarnet is another drug that may be used when resistant strains of HSV arise. It
is a pyrophosphate analog and is not dependent on either the viral or host cell kinases. By
being a competitive inhibitor of pyrophosphate binding sites on the viral DNA
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polymerase, it is able to successfully halt DNA synthesis. Unfortunately, Foscarnet has
been linked to serious renal toxicity and close monitoring of patient’s serum creatinine
levels need to be maintained during therapy. Yet again, the virus has also learned to
overcome the effects of Foscarnet by causing point mutations in the viral DNA
polymerase (Bacon et al., 2003; Brady and Bernstein, 2004; Snoeck, 2000).
Overall, due to the rise of HSV resistant strains, there is a desperate need to
develop novel antiviral treatments. Management of HSV infections can be effectively
achieved if HSV shedding is prevented.

Herpes Simplex Virus 1 &2 Vaccines
Although current antiviral drugs can treat HSV symptoms and disease, they do
not prevent recurrence. Thus, several attempts have been made in search for a vaccine
that will prevent initial as well as the establishment of latent infections (Bernstein and
Stanberry, 1999; Quenelle et al., 2006). Although constant efforts have been taken to
obtain a vaccine since 1920, further research still needs to be conducted. Up to date,
many vaccines that showed to be effective in vitro and in animal models, failed during
clinical trials (Belshe et al., 2012; Chentoufi et al., 2012). Thus, while the strive for
obtaining a vaccine continues, efforts should also be put into creating novel antiviral
treatments that may serve as a way to substitute or complement current antiviral
medications, and in turn, prevent transmission of the virus.
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Benefits of Tea Polyphenols
Tea consumption dates back to as early as 2700 BC (Taylor et al., 2005). Over
two thirds of the world’s population consume tea, in particular the ones derived from the
Camellia sinensis plant and take advantage of the many health benefits they provide
(Sumit et al., 2013). Although tea has always been used as a form of crude medicine, its
actual health benefits have just recently begun to be scientifically studied (Dufresne and
Farnworth, 2001; Sumit et al., 2013). Tealeaves contain metabolites, including catechins,
which are believed to aid the plant in the fight against pathogens such as bacteria, fungi
and viruses. These catechins, also contain potent activity against a variety of human
health diseases, and for this reason, they have been the focus of many studies (Friedman,
2007).
There are three different types of tea that are commonly derived from the leaves
of the Camellia sinensis plant. These include, green tea (unfermented and contains
catechins), black tea (fully fermented and contains catechins, theaflavins and
thearubigins), and oolong tea

(partially fermented and contains catechins and

theaflavins) (Dufresne and Farnworth, 2001). The differences in tea arise from the way
they are postharvest processed. In order for drying to occur, tealeaves are exposed to air,
resulting in oxidation, and fermentation. Through the fermentation process, the catechins
found in unfermented tea are polymerized, giving rise to theaflavins and thearubigins.
Thus, the amount of fermentation determines the type of tea it will become, and the
flavanoids it will contain. In contrast, the process of stopping fermentation is commonly
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obtained by heating and dehydration, which inactivates enzymes in the tealeaves such as
phenol oxidases (Friedman, 2007; Sharangi, 2009).

Natural Tea Polyphenols as possible HSV-1/ HSV-2 Therapeutic Agents
Currently, there is a great concern over the rising strains of drug resistant
microorganisms. Due to the lack of response to the drugs we currently have in the market,
there is a desperate need to develop novel antiviral treatments. There is no cure for the
diseases caused by HSV infections.

While the majority of HSV infections are

asymptomatic, individuals are unknowingly shedding virus and can contribute to the
spread of HSV (Mertz, 2008). More importantly, HSV infection could be diminished if
effective antivirals that block infection and prevent viral shedding are developed (Morfin
and Thouvenot, 2002).
Over the past years, green tea has been the center of many studies due to its
richness in catechin polyphenols, including epigallocatechin gallate (EGCG),
epigallocatechin (EGC), epicatechin gallate (ECG) and epicatechin, with EGCG being
the most abundant catechin (Dufresne and Farnworth, 2001; Nagle et al., 2006).
Green tea’s most studied polyphenol, EGCG (Fig. 5), has been shown to have
many pharmacological activities including anticancer, antiviral, antibacterial and antiinflammatory activity (Imai et al., 1997; Mukhtar and Ahmad, 2000; Sueoka et al., 2001;
Zu et al., 2012). Among the antiviral potentialities of EGCG are influenza virus, HIV-1,
as well as HSV-1 and HSV-2 (Isaacs et al., 2008; Steinmann et al., 2013; Williamson et
al., 2006). When Vero cells were infected with HSV-1 and HSV-2, EGCG successfully
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inhibited infection of HSV-1 by 3,000 fold and HSV-2 by 10,000 fold in a concentration
dependent manner. Although other green tea catechins were also tested, only EGCG
produced the inhibitory effect (Isaacs et al., 2008).

However, EGCG in its original

chemical forms is highly unstable and oxidizes easily, losing its antiviral efficiency long
before one would be able to use it. Also, EGCG is water-soluble and one would not be
able to take advantage of its benefits by using it as a topical application. However, fatty
acid esters modified polyphenols may be used as an effective antiviral agent as an
ingredient in lipophilic preparations (Chen et al., 2009). A study done using influenza
virus showed that EGCG lipid esters are 24 times more effective than EGCG as inhibitors
and inactivators of the influenza virus (Mori et al., 2008). Thus, the same could
potentially be seen against HSV. EGCG lipid esters (Fig. 6) may be a safe, non-toxic
novel candidate for HSV antiviral agents for topical application.
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(CH2)14CH3

Although not extensively studied as green tea, black tea has also been shown to
contain many health benefits. Black tea is rich in theaflavin polyphenols due to the fully
fermentation process of the tealeaves. Black tea extract contains theaflavins along with
thearubigins, flavanols, alkaloids, and amino acids (Sharangi, 2009). Theaflavins are
what accounts for the black teas’ distinct flavor, color and antimicrobial activity. The
theaflavins found in black tea include theaflavin (TF1), theaflavin-3-monogallate
(TF2A), theaflavin-3′-monogallate (TF2B), and theaflavin-3,3′-digallate (TF3) (Fig. 7)
(Sumit et al., 2013).
Studies have shown that theaflavins have the ability to protect cells from
oxidative damage (Akram et al., 2012; Almajano et al., 2008), inhibit certain types of
cancer such as breast cancer (Adhikary et al., 2010) and prostate cancer (Henning et al.,
2006), as well as some viruses including poliovirus 1, rotaviruses (Mukoyama et al.,
1991; Nakayama et al., 1993), influenza virus (Zu et al., 2012) and HIV-1 (Yang et al.,
2012). Just recently a mixture of theaflavin was shown to be effective against HSV-1
(Cantatore et al. (2013), but the effect of each individual theaflavin and the mode of
action was still to be studied. The ability to pinpoint the efficacy of each individual
theaflavin is essential in order to fully understand the anti-HSV-1 and HSV-2 effect of
theaflavins.
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Figure 7: Structures of black tea theaflavins, TF1, TF2 (TF2A and TF2B), and TF3. “Reprinted
from Antiviral Research, Volume 118, Aline de Oliveira, Derek Prince, Chih-Yu Lo, Lee H. Lee,
Tin-Chun Chu, Antiviral activity of theaflavin digallate against herpes simplex virus type 1, 5667, Copyright (2015), with permission from Elsevier, License number 3856721491636.”
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With the current rise of HSV resistant strains, and the immediate need to develop
new antiviral therapies, this study aimed to identify and analyze natural candidates found
in herbal tea, which could potentially replace or be used in addition to current HSV
medications. Comprehensive research on purified green tea polyphenol, EGCG and its
modified version, p-EGCG, as well as purified black tea theaflavins TF1, TF2 and TF3
were carried out to examine their effect against HSV-1 and HSV-2. This study was
conducted using two different mammalian cell lines, including Vero (green monkey
kidney cells) and A549 (adenocarcinoma human alveolar basal epithelial cells).
In order to test the effect of EGCG and p-EGCG as anti- HSV-1 and HSV-2
agents, we first identified and analyzed any effect these compounds may have had on in
vitro cultures of Vero and A549 cells. To do so, cytotoxicity tests such as cell viability,
cell morphology and cell proliferation assays were carried out to observe and or to
measure the responses based on different concentrations of each of the compounds. Next,
we sought to identify, analyze and compare any effect EGCG and or p-EGCG may have
on HSV-1 and HSV-2 infections on in vitro cultures of Vero and A549 cells. This
involved running different antiviral tests and observing and or measuring the responses
based on different concentrations of each of the compounds. The concentrations and
times of exposure used were based on the cytotoxicity results. To test potential antiherpes
effect of EGCG and p-EGCG on infected Vero and A549 cells, several different assays
were performed, including viral titer determination using plaque assay, fluorescence
microscopy study, flow cytometry study, and PCR/ qPCR of genomic viral DNA. Finally,
upon concluding that p-EGCG is more efficient in inhibiting HSV in both cell lines, we
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sought to identify and characterize the mechanism of p-EGCG as anti-HSV-1 and HSV-2
agents. This involved performing binding, adsorption assays to test its potential in
inhibiting the virus at the binding stage of infection.
Upon observing that green tea polyphenols were highly effective against HSV-1
and HSV-2 infection in Vero and A549 cells, we sought to experiment with black tea
theaflavins (TF1, TF2, and TF3). In order to test the effect of each theaflavin as antiHSV-1 and HSV-2 agents, we first identified and analyzed any effect these compounds
may have on in vitro cultures of Vero and A549 cells. Cytotoxicity tests such as cell
morphology and cell proliferation assays were carried out to observe and or to measure
the responses based on different concentrations of each of the compounds. Next, we
sought to identify, analyze and compare any effect TF1, TF2, and TF3 may have on
HSV-1 and HSV-2 infections on in vitro cultures of Vero and A549 cells. This involved
running similar antiviral tests that were used for the green tea compounds, which
included plaque assay, fluorescence microscopy study, flow cytometry study, and qPCR
of genomic viral DNA. Upon concluding that all three theaflavins were successful in
inhibiting HSV infection in both of the cell lines used, with TF3 showing the most effect,
we pursued understanding of the underlying mechanism of TF3. This involved infecting
the cells with the compound-treated virus at different time points, and observing the viral
life cycle in order to determine the time and place at which the virus was being inhibited.
The concentrations and times of exposure were based on the antiviral tests. To further
characterize the mechanism of TF3 as anti-HSV-1 and HSV-2 compound, three other
assays were be performed, including binding, adsorption and SEM observations.

23

Materials and Methods
Cell culture maintenance
Green monkey kidney cells (Vero) and Human lung adenocarcinoma epithelial
cells (A549) were used in all assays (purchased from ATCC, Manassas, VA). Vero cells
were cultured in T-75 flasks until confluent with Dubelcco’s Minimal Essential Media
(DMEM) with 5% Fetal Bovine Serum (FBS) and 1 μg/ml gentamicin at 37 °C and 5%
CO2. A549 cells were cultured in T-75 flasks until confluent with 1X Ham’s F-12K
nutrient media, Kaighn’s modification with 2 mM L-glutamine, with 10% FBS and 1%
penicillin at 37 °C and 5% CO2.

HSV-1 and HSV-2 maintenance
To study the HSV-1 life cycle, a recombinant strain of HSV-1 (GHSV-UL46) was
used (kindly provided by Dr. Sandra Adams; Department of Biology and Molecular
Biology, Montclair State University, Montclair, NJ 07043, USA). This viral strain
contains the HSV-1 tegument protein pUL46 gene fused to green fluorescent protein
(GFP) (Willard, 2002). Cells were grown in T-75 flasks and allowed to reach complete
cytophatic effect (CPE) upon viral infection. The virus containing media was then
centrifuged, the supernatant was aliquoted into cryogenic vials and stored at -80 °C.
To study the HSV-2 life cycle, a recombinant strain of HSV-2 (HSV2-VP26GFP) was used (kindly provided by Dr. Andrea Bertke; Virginia Tech, Blacksburg, VA
24060 USA). This viral strain contains the HSV-2 capsid protein UL35 gene fused to
GFP (Desai and Person, 1998). Cells were grown in T-75 flasks and allowed to reach
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complete cytophatic effect (CPE) upon viral infection. The virus containing media was
then centrifuged, the supernatant was aliquoted into cryogenic vials and stored at -80 °C.

Preparation of EGCG, p-EGCG, TF1, TF2, TF3 solution
Purified EGCG, and p-EGCG were kindly obtained from Dr. Stephen Hsu
(Georgia Regents University, Augusta, GA 30912, USA). Purified TF1, TF2, and TF3
were generously provided by Dr. Chih-Yu Lo (National Chiayi University, Chiayi City,
Taiwan).

Each polyphenol was dissolved in DMSO to produce a 5 mM stock

concentration. Stock solutions were further diluted in media to obtain appropriate
concentrations of 12.5, 25, 50, and 75 μM.

Observation of cell morphology
Vero and A549 cells were grown in 60 mm dishes for 24 h at 37 °C and 5% CO2.
Cells were then treated with 12.5, 25, 50, and 75 μM of each polyphenol for 1 h.
Unadsorbed polyphenols were removed and cells were washed with phosphate buffer
saline (PBS). Fresh media was added and cells were incubated for 24 h at 37°C and 5%
CO2. Cells were then examined for morphological changes using an AmScope IN200B
microscope with an attached camera by comparing treated and untreated samples.

Determination of cell viability
Vero cells were plated on 6-well plates and allowed to grow for 24 h. Cells were
then treated with different concentrations of EGCG or p-EGCG (12.5, 25, 50, 75 μM) and
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incubated at 37 °C and 5% CO2 for 1 h. Unadsorbed polyphenols were aspirated and the
cells washed with PBS. Fresh media was added to the wells and the cells incubated for 24
h at 37 °C and 5% CO2. Finally, the cells were trypsinized and harvested. The cell
viability was determined by using 1:1 dilution of trypan blue and conducting direct cell
count using a hemacytometer. The viability was determined as the percentage of viable
(non-stained) cells at different treatments, compared to the control level.

Determination of cytotoxicity
A tetrazolium reduction-based kit (G5421, Promega Corp.) was used to determine
cellular cytotoxicity. This kit contains a tetrazolium compound and an electron-coupling
reagent (phenazine methosulfate). Only live cells are able to bioreduce the tetrazolium
compound into soluble formazan. Thus, the amount of formazan formed and measured at
490 nm absorbance is directly proportional to the number of live cells. Vero and A549
cells were plated in 96 well plates and allowed to reach 70-80% confluency. Cells were
then treated with different concentrations (12.5, 25, 50, 75 μM) of EGCG, p-EGCG, TF1,
TF2, and TF3 in triplicates for 1 h. Unadsorbed polyphenols were aspirated and fresh
media was added to the wells. Cells were allowed to proliferate for 24 h at 37 °C and 5%
CO2.

A plate reader was then used to assess cell viability/proliferation by

spectrophotometric determination of absorbance at 490 nm. The proportion of absorbance
of treated cells compared to untreated (100% proliferation) was used as a basis to
determine percent cell proliferation.
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Viral titer determination using plaque assay
Vero and A549 cells were plated in 35 mm dishes and allowed to reach
confluence at 37 °C and 5% CO2. HSV-1 and HSV-2 virions were treated with different
concentrations (12.5, 25, 50, 75 μM) of each polyphenol for 1 h at 37 °C and 5% CO2
prior to infection. Cells were then infected with serial dilutions (10-1 to 10-6) of 100 μL
treated or untreated virions and allowed to absorb for 1 h at 37 °C, 5 %CO2. Unabsorbed
virions were aspirated and cells were washed with PBS. Cells were then overlaid with a
medium-containing agar and incubated for 50 h at 37 °C, 5% CO2. Cells were fixed with
12.5% formaldehyde in phosphate buffer for 48 h. A 0.1% crystal violet solution was
used to stain plaques and allow visualization. Plaques assay was carried out in triplicate.

Fluorescence microscopy study
Vero and A549 cells were grown on sterile glass cover slip and allowed to reach
70-80% confluence. Cells were then infected with treated (75 μM TF3, 75 μM p-EGCG)
or untreated HSV-1 and HSV-2 virions for 1 h at 37° C, 5% CO2. Unadsorbed virions
were aspirated and cells were washed with PBS. Cells were incubated at 37 °C, 5% CO2
for 12 h and viral life cycle allowed to progress. Cells were then washed with PBS and
stained with 300 μL of 300 nM DAPI (4,6-diamidino-2-phenylindole) for 5 min at room
temperature in the dark. Cells were once again washed with PBS and were fixed with a
1:1 acetone/methanol solution for 20 min at -20° C. The glass cover slips were then
retrieved and 20 μl of glycerol was used as the mounting medium. Cells were analyzed
using an Olympus Fluoview FV-1000confocal laser-scanning microscope (CLSM).
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Flow cytometry antiviral study
Vero and A549 cells were grown in 60 mm dishes for 24 h. HSV-1 and HSV-2
virions were treated with different polyphenol concentrations (0, 6.25, 12.5, 25, 50, 75
μM) for 1 h at 37 °C, 5% CO2 prior to infection. The cells were then infected with treated
or untreated virions for 1 h at 37 °C, 5% CO2. Unabsorbed virions were then aspirated
and cells were washed with PBS. Cells were incubated at 37 °C, 5% CO2 for an
additional 12 h in fresh media. Cells were then trypsinized and resuspended in PBS for
flow cytometric analysis. Flow cytometry antiviral assay was carried out using a
MACSQuant Analyzer, serial #MQ2492 (MACS Miltenyi Biotec) in triplicate.

DNA extraction of HSV-1 and HSV-2 infected cells
Vero and A549 cells were plated in 60 mm cell culture dishes and allowed to
reach confluence. HSV-1 and HSV-2 virions were treated with different concentrations
(0, 12.5, 25, 50, 75 μM) of polyphenols for 1 h at 37 °C, 5% CO2 prior to infection. The
cells were then infected with HSV-1 and HSV-2 virions (MOI 1:1) for 1 h at 37°C, 5%
CO2. Unabsorbed virions were aspirated and cells washed with PBS. Fresh media was
added and cells incubated for 12 h at 37 °C, 5% CO2. Cells were then trypsinized and
DNA extracted using the Qiagen Dneasy Blood and Tissue Kit (Qiagen Sciences,
Germantown, MD, USA) according to the protocol provided. DNA concentration for
each sample was assessed using a NanoDropTM 1000 Spectrophotometer (Thermo
Scientific, Wilmington, DE USA).
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Primer design, polymerase chain reaction (PCR)
To study the effect of EGCG and p-EGCG on HSV-1 viral replication, PCR
reaction was used. Three sets of primers were designed to prime different regions of the
HSV-1 genome, including HSV-1 US6 (encoding glycoprotein D), HSV-1 GFP, and
HSV-1 UL46 (encodingVP11/VP12) genes based on published sequences (Table 1). The
PCR amplification method used for amplifying 25 μL reactions included an initial
denaturation at 95 °C for 2 min, followed by 30 cycles of denaturation at 95 °C for 30 s,
annealing at 60 °C for 1 min and extension at 72 °C for 30 s, followed by a final
extension period at 72 °C for 10 min. Gel electrophoresis was used in order to confirm
correct amplicon sizes. The densities of the amplicons were analyzed under UV light
using Kodak Image Station 440CF (Perkin Elmer Life Science, Waltham, MA).

Quantitative PCR (qPCR)
Three sets of primers that amplify the HSV-1 and HSV-2 US6 gene (encoding
glycoprotein D) and one set of primer that amplifies the HSV-2 UL7 gene (encoding
glycoprotein B) were designed for use in qPCR reaction (Table 2). The amplification
methods used include an initial holding at 95 °C for 5 min, followed by 40 cycles of
denaturation at 95 °C for 15 s, annealing at 60 °C for 1 min, and extension at 72 °C for
30 sec. The samples were run on ABI StepOnePlus Real-Time PCR System (Applied
Biosystems; Carlsbad, CA). The quantitative PCR analysis was carried out in triplicate
including negative controls.
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Table 1: HSV-1 primers used in PCR-based assays.
Primers

Target genes

gD1

HSV-1 US6

GFP

HSV-1 GFP

VP11/12

HSV-1 US46

Fwd.
Rev.
Fwd.
Rev.
Fwd.
Rev.

Nucleotide sequence (5’ to 3’)
AGACGTCCGGAAACAACCCTACAA
ACACAATTCCGCAAATGACCAGGG
TGACCCTGAAGTTCATCTGCACCA
AACTCCAGCAGGACCATGTGAT
ACCAAGCCTTGATGCTCAACTCCA
ACAACACGGTTCCCGAGAGTTTGA

Tm (°C)
64.6
64.6
64.6
62.7
64.6
64.6

Amplicon (nt)
752
717
957

“Reprinted from Food and Chemical Toxicology, Volume 52, Aline de Oliveira, Sandra D. Adams, Lee H. Lee, Sean R. Murray, Stephen
D. Hsu, Jeffrey R. Hammond, Douglas Dickinson, Ping Chen, Tin-Chun Chu, Inhibition of herpes simplex virus type 1 with the modified
green tea polyphenol palmitoyl-epigallocatechin gallate, 207-215, Copyright (2013), with permission from Elsevier, License number
3856720963132.”

Table 2: HSV-1 and HSV-2 primers used in qPCR-based assays.
Primers

Target genes

gD1

HSV-1 US6

gD1

HSV-2 US6

gD2

HSV-2 US6

gB1

HSV-2 L27

Fwd.
Rev.
Fwd.
Rev.
Fwd.
Rev.
Fwd.
Rev

Nucleotide sequence (5’ to 3’)
CAACCCTACAACCTGACCATC
TTGTAGGAGCATTCGGTGTAC
GGATAACCTGGGATTCCTGATG
GATCTCCGTCCAGTCGTTTATC
TCGTGTGCATCGCGTATC
GGGTCTGCTAAGGCGTATTT
CAAGGTAGTCATGGGAGTAGTG
GTAGCGGAAGGCGAAGAA
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Tm (°C)
62.0
62.0
62.7
62.7
59.9
60.4
62.7
59.9

Amplicon (nt)
115
91
118
142

Binding assay
Vero and A549 cells were plated in 35 mm cell culture dishes and allowed to
reach confluence. HSV-1 and HSV-2 virions were treated with different concentrations of
p-EGCG and TF3 (50, 75 μM) for 1 h at 37 °C, 5% CO2 prior to infection. The cells were
then infected with serial dilutions (10-1 to 10-6) of 100 μL treated or untreated virions for
1 h at 4 °C, a temperature that allows HSV virions to bind to cell receptors but prevents
them from penetrating the cells. Unabsorbed virions were aspirated and the cells washed
with PBS twice. Cells were overlaid with a medium-containing agar and incubated for 50
h at 37 °C, 5% CO2. Cells were then fixed with 12.5% formaldehyde in phosphate buffer
for 48 h. Cells were stained with 0.1% crystal violet and plaques were counted. Binding
assay was carried out in triplicate.

Penetration assay
Vero and A549 cells were plated in 35 mm cell culture dishes and allowed to
reach confluence. The cells were then infected with serial dilutions (10-1 to 10-6) of 100
μL untreated virions for 1 h at 4 °C, a temperature that allows HSV virions to bind to cell
receptors but prevents them from penetrating the cells. Unbound virions were aspirated
and the cells washed with PBS twice. Cells were then treated with different
concentrations of p-EGCG and TF3 (50, 75 μM) and placed at 37 °C for 1 h,
atemperature that allows the bound virions to penetrate the cells. Unabsorbed virions
were aspirated and cells were washed with PBS twice. Cells were then overlaid with a
medium-containing agar and incubated for 50 h at 37 °C, 5% CO2. Cells were fixed with
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12.5% formaldehyde in phosphate buffer for 48 h. Cells were stained with 0.1% crystal
violet and plaques were counted. Penetration assay was carried out in triplicate.

Binding/adsorption flow cytometry study
Vero and A549 cells were grown in 35 mm dishes for 24 h. In order to assess the
effect of 75 μM p-EGCG and TF3 on HSV-1 and HSV-2 viral binding/adsorption, the
cells were treated at different time points of the virus life cycle. First, both virions were
treated with 75 μM p-EGCG and TF3 for 1 h prior to infection. Vero and A549 cells only
were also treated with 75 μM p-EGCG and TF3 prior to infection. Then, Vero and A549
cells were treated at different time points post infection (0, 2, 4, 6, 8, 10 h). Unabsorbed
virions were then aspirated and cells were washed with PBS. Cells were incubated at 37
°C, 5% CO2 for an additional 12 h in fresh media. Cells were then trypsinized and
resuspended in PBS for flow cytometric analysis. Flow cytometry antiviral assay was
carried out in triplicate.

Scanning electron microscopy (SEM) study
Sample fixation
Vero cells were grown on cover slips and infected with either treated or untreated
75 μM TF3 HSV-2 for 1 h at 37 °C, 5% CO2. The unadsorbed virus was aspirated and
cells washed with PBS. Cells were incubated for 24 h at 37 °C, 5% CO2. The cells were
then washed with PBS and fixed with 2.5% glutaraldehyde working stock (GTA) and 0.1
M cacodylate buffer. Samples were stored overnight at 4 °C.
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Sample dehydration
Cells were washed with 0.1 M cacodylate buffer 3 times. Unabsorbed buffer was
aspirated, and 2 mL of 1% Osmium tetroxide (OsO4) solution added to each sample at 4
°C for 45 min. Unabsorbed OsO4, was aspirated and 0.1 M cacodylate buffer added to the
samples for 10 min 3 times. The cells were then dehydrated with a series of EtOH washes
(30%, 50%, 70%, 80%, 90% and then 100%) for 10 min between each wash.

Critical point drying and coating
The cells were dried for 40 min with the help of carbon dioxide. The samples
were then coated in gold for 10 min and SEM images were taken.

Statistical analyses
All assays were performed in triplicate and the data analyzed using one way
Analysis of Variance (ANOVA), and Dunnet’s comparison test (p < 0.05) by GraphPad
Prism 5 software. This test was used throughout the study since it focuses on differences
found between each treatment and the control group, and not treatments against
treatments (Rumsey, 2009). It creates confidence intervals for the difference found after
analyzing the mean of each treatment and the mean of the control group.
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Results
Cytopathic

monitoring

studies

indicate

that

EGCG

and

p-EGCG

with

concentrations up to 75 μM have no significant effect on Vero and A549 cell
morphology.
Cytopathic studies were conducted to evaluate the effect of various concentrations
(12.5, 25, 50, 75 μM) of EGCG and p-EGCG on Vero and A549 cells. As seen in Fig. 8
and 9, no morphological abnormalities or cytotoxicity characteristics were observed at
any of the concentrations tested. Treatment of Vero and A549 cells with concentrations
up to 75 μM EGCG or p-EGCG showed similar cellular morphologies to the untreated
cells (Fig. 8 A, A’ and Fig. 9 A, A’).
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Figure 8. Cytopathic monitoring assay. Phase contrast microscopy of Vero and A549 cells
treated with different concentrations of EGCG. (A) Vero cells only, (A’) A549 cells only; (B)
DMSO treated Vero cells, (B’) DMSO treated A549 cells; (C) 12.5 μM EGCG treated Vero cells,
(C’) 12.5 μM EGCG treated A549 cells; (D) 25 μM EGCG treated Vero cells, (D’) 25 μM EGCG
treated A549 cells; (E) 50 μM EGCG treated Vero cells, (E’) 50 μM EGCG treated A549 cells;
(F) 75 μM EGCG treated Vero cells, (F’) 75 μM EGCG treated A459 cells.
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Figure 9. Cytopathic monitoring assay. Phase contrast microscopy of Vero and A549 cells
treated with different concentrations of p-EGCG. (A) Vero cells only, (A’) A549 cells only; (B)
DMSO treated Vero cells, (B’) DMSO treated A549 cells; (C) 12.5 μM p-EGCG treated Vero
cells, (C’) 12.5 μM p-EGCG treated A549 cells; (D) 25 μM p-EGCG treated Vero cells, (D’) 25
μM p-EGCG treated A549 cells; (E) 50 μM p-EGCG treated Vero cells, (E’) 50 μM p-EGCG
treated A549 cells; (F) 75 μM p-EGCG treated Vero cells, (F’) 75 μM p-EGCG treated A459
cells.
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Cell viability assay indicate that p-EGCG with concentrations up to 75 μM have no
significant effect on Vero cell viability.
Vero cell viability was determined by using trypan blue, which stains dead cells
blue. A hemocytometer was also used for direct cell count and detection of cell viability
upon treatments with EGCG or p-EGCG was obtained. The viability was determined as
the percentage of viable (non-stained) cells at different treatments, compared to the
control level. As shown in Fig. 10, cell viability assay shows that p-EGCG does not
reduce Vero cell viability. As seen, a minimum of 98.86% of the cells remains viable
after 1 h of treatment with p-EGCG at concentrations up to 75 μM. The viability of the
treated cells was similar to the control. As the concentration of p-EGCG is increased, the
percentage of cell death does not increase. Similar numbers of cells were recovered at all
concentrations of EGCG tested. Thus, concentrations up to 75 μM can be safely used to
investigate its inhibitory effect against HSV-1 and HSV-2.
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Figure 10. Cell viability of Vero cells treated with different concentrations (12.5, 25, 50, 75 μM)
of p-EGCG. The numbers represent the mean of three replicates and the y-error bars represent SD.
“Reprinted from Food and Chemical Toxicology, Volume 52, Aline de Oliveira, Sandra D.
Adams, Lee H. Lee, Sean R. Murray, Stephen D. Hsu, Jeffrey R. Hammond, Douglas Dickinson,
Ping Chen, Tin-Chun Chu, Inhibition of herpes simplex virus type 1 with the modified green tea
polyphenol palmitoyl-epigallocatechin gallate, 207-215, Copyright (2013), with permission from
Elsevier, License number 3856720963132.”
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Cell proliferation assay (MTS) shows that EGCG and p-EGCG with concentrations
up to 75 μM have no significant effect on Vero and A549 cell proliferation.
Vero and A549 cells were exposed to different concentrations (12.5, 25, 50, 75
μM) of EGCG and p-EGCG for 1 h and then observed for possible cytotoxic and or
proliferation effects 24 h later (Fig. 11). The percent cell proliferation was assessed based
on the OD490nm for triplicate tests for each polyphenol. Exposing Vero and A549 cells to
75 μM p-EGCG tested, inhibited cell proliferation by ~ 10%, which is less than the effect
on proliferation levels seen with EGCG. The results acquired are consistent with the
minor decrease in cell viability (p < 0.05) seen by direct counting of p-EGCG treated
cells (Fig. 10). Thus, Vero and A549 cells exposed to high concentrations of EGCG and
p-EGCG are competent for cell proliferation, suggesting that these compounds are not
toxic to Vero and A549 cells and can be used to further investigate their inhibitory effect
against HSV-1 and HSV-2.
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Figure 11. Cell viability and proliferation studies of Vero and A549 cells treated with different
concentrations (0, 12.5, 25, 50 and 75 μM) of EGCG and p-EGCG using MTS assay. The means
of results of triplicate tests of Vero cells samples (stripped) and A549 cells samples (solid)
represent the average of triplicate trials. The y-error bars represent SD.
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Plaque assay shows that p-EGCG is more effective in reducing HSV-1 plaque
formation in Vero cells compared to EGCG.
To determine the change in HSV-1 titer upon treatment with either EGCG or pEGCG, a plaque assay was performed. As seen in Fig. 12, modification of the green tea
polyphenol EGCG with palmitate increases the effectiveness of EGCG as an antiviral
agent. Treating HSV-1 with 50 μM EGCG decreased PFU/ml by 92.15 ± 0.15%.
Outstandingly, treatment with 50 μM p-EGCG resulted in no detectable plaques; that is, a
greater than 99% reduction in plaque formation (p < 0.05). Thus, the results suggest that
palmitoylation of EGCG increases its HSV-1 antiviral activity.
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Figure 12. Plaque assay of (A) HSV-1/Vero, (B) HSV-1 treated with 50 μM EGCG/Vero, (C)
HSV-1 treated with 50 μM p-EGCG/Vero. (D) PFU of HSV-1/Vero, HSV-1 treated with 50 μM
EGCG/Vero, and HSV-1 treated with 50 μM p-EGCG/Vero. There is significant difference
between tests and control (p < 0.05). The numbers represent the mean of triplicates and the yerror bars represent SD. “Reprinted from Food and Chemical Toxicology, Volume 52, Aline de
Oliveira, Sandra D. Adams, Lee H. Lee, Sean R. Murray, Stephen D. Hsu, Jeffrey R. Hammond,
Douglas Dickinson, Ping Chen, Tin-Chun Chu, Inhibition of herpes simplex virus type 1 with the
modified green tea polyphenol palmitoyl-epigallocatechin gallate, 207-215, Copyright (2013),
with permission from Elsevier, License number 3856720963132.”
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Plaque assay shows that 50 μM p-EGCG effectively inhibits HSV-1 plaque
formation in Vero cells
To determine the range of concentrations of p-EGCG that effectively inhibit
HSV-1, a plaque assay was once again performed. As shown in Fig. 13 (B), exposure of
viral particles to 12.5 μM p-EGCG caused a 51.89 ± 2.66% decrease in HSV-1 PFU;
exposure to 25 μM p-EGCG caused a 80.16 ± 1.38% decrease in HSV-1 PFU, and
exposure to p-EGCG at concentrations above 50 μM resulted in a > 99% decrease in titer.
The plaque forming units were significantly different from the control (p < 0.05).
Collectively, these experiments demonstrated that non-toxic concentrations of EGCG or
p-EGCG could effectively inhibit the ability of HSV-1 to complete its lytic cycle. Since
both 50 and 75 μM concentrations of p-EGCG resulted in a > 99% decrease in titer and
were found to be non-toxic to Vero cells, a concentration of 75 μM of p-EGCG was
chosen to be used in subsequent experiments.
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Figure 13. (A) Plate of PFU of HSV-1 treated with different concentrations of p-EGCG. (B)
Graph showing PFU of HSV-1 treated with different concentrations (12.5, 25, 50, 75 μM) of pEGCG. There is significant difference between tests and control (p < 0.05). The numbers
represent the mean of triplicate trials and the y-error bars represent SD. “Reprinted from Food
and Chemical Toxicology, Volume 52, Aline de Oliveira, Sandra D. Adams, Lee H. Lee, Sean R.
Murray, Stephen D. Hsu, Jeffrey R. Hammond, Douglas Dickinson, Ping Chen, Tin-Chun Chu,
Inhibition of herpes simplex virus type 1 with the modified green tea polyphenol palmitoylepigallocatechin gallate,, 207-215, Copyright (2013), with permission from Elsevier, License
number 3856720963132.”
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Fluorescence microscopy study demonstrates that 75 μM of p-EGCG is effective in
inhibiting HSV-1/ GFP expression in Vero cells
To further study the inhibitory effect of p-EGCG on HSV-1 infected Vero cells,
fluorescence microscopy was used. As seen in Fig. 14-16, fluorescence microscopy
confirms the effectiveness of EGCG and p-EGCG against HSV-1 infection of Vero cells.
Non-infected Vero cells showed a typical flattened ‘‘cobblestone’’ epithelial pattern of
growth, and the DAPI-stained nuclei had smooth margins with no evident granules; green
fluorescent granules (viral particles) were absent as shown in Fig. 14. In contrast, Vero
cells 8 to 12 h post-infection with untreated HSV-1 showed significant morphological
changes typical of lytic viral infection (Fig. 15). A significant level of GFP expression
was observed, and there were numerous fluorescent clusters of viral particles. GFP
positive granules could be observed through 12 h post-infection and looked very similar
at 8 or 10 h post infection. The cells were rounded, and the nuclei showed significant
granulation and loss of margins. The extent of nuclear granulation and margin loss
continued to increase through 12 h post infection (Fig. 16). The morphology of cells
infected with virions treated with 75 μM p-EGCG closely resembled non-infected cells at
all time points. The cells maintained their flattened cobblestone appearance, and the
nuclei remained intact. Relatively few GFP positive granules could be seen. Together,
these observations indicate that treatment of HSV-1 virus particle with 75 μM p-EGCG
prevented completion of the lytic cycle in Vero cells.
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Figure 14. Fluorescence microscopic observations of control Vero cells (400X). (A) Phase
contrast; (B) DAPI stain; (C) GFP. “Reprinted from Food and Chemical Toxicology, Volume 52,
Aline de Oliveira, Sandra D. Adams, Lee H. Lee, Sean R. Murray, Stephen D. Hsu, Jeffrey R.
Hammond, Douglas Dickinson, Ping Chen, Tin-Chun Chu, Inhibition of herpes simplex virus type
1 with the modified green tea polyphenol palmitoyl-epigallocatechin gallate, 207-215, Copyright
(2013), with permission from Elsevier, License number 3856720963132.”
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Figure 15. GFP expression observation of HSV-1 infected Vero cells (A-C) and Vero cells
infected with 75 μM p-EGCG treated HSV-1 (A’-C’) at 8–12 h post-infection. (A) 8 h no pEGCG; (A’) 8 h + p-EGCG; (B) 10 h no p-EGCG; (B’) 10 h + p-EGCG; (C) 12 h no p-EGCG;
(C’) 12 h + p-EGCG. “Reprinted from Food and Chemical Toxicology, Volume 52, Aline de
Oliveira, Sandra D. Adams, Lee H. Lee, Sean R. Murray, Stephen D. Hsu, Jeffrey R. Hammond,
Douglas Dickinson, Ping Chen, Tin-Chun Chu, Inhibition of herpes simplex virus type 1 with the
modified green tea polyphenol palmitoyl-epigallocatechin gallate, 207-215, Copyright (2013),
with permission from Elsevier, License number 3856720963132.”
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Figure 16. DAPI stain observation of HSV-1 infected Vero cells (A-C) and Vero cells infected
with 75 μM of p-EGCG treated (A’-C’) at 8–12 h post-infection. (A) 8 h no p-EGCG; (A’) 8 h +
p-EGCG; (B) 10 h no p-EGCG; (B’) 10 h + p-EGCG; (C) 12 h no p-EGCG; (C’) 12 h + p-EGCG.
The arrows show the granulation and loss of margins in the HSV-1 infected cells. “Reprinted
from Food and Chemical Toxicology, Volume 52, Aline de Oliveira, Sandra D. Adams, Lee H.
Lee, Sean R. Murray, Stephen D. Hsu, Jeffrey R. Hammond, Douglas Dickinson, Ping Chen, TinChun Chu, Inhibition of herpes simplex virus type 1 with the modified green tea polyphenol
palmitoyl-epigallocatechin gallate, 207-215, Copyright (2013), with permission from Elsevier,
License number 3856720963132.”
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PCR and qPCR of genomic HSV-1 DNA suggests that p-EGCG reduces the
replication of HSV-1 viral genes
To study the effect of EGCG and p-EGCG on viral replication, PCR and qPCR
reaction were used. As seen in Fig. 17, PCR amplification of HSV-1 genes encoding
glycoprotein D, GFP and VP11/12 12 h post infection upon treatment with 75 μM EGCG
or p-EGCG Vero cells suggests that the replication of the viral genes is reduced, with pEGCG treatment being the most effective.
Next, since PCR suggested a reduction in the levels of viral genomic DNA,
quantitative real-time PCR of the viral US6 gene encoding glycoprotein D was therefore
used to quantify the relative block of viral DNA replication 12 h after infection with
EGCG or p-EGCG treated virions. As seen in Fig. 18, real time PCR reaction further
confirms that EGCG and p-EGCG treatments block the replication of the viral genes
encoding glycoprotein D. Treatment with EGCG caused a 95% reduction in the
concentration of HSV-1’s US6 gene relative to concentration in Vero cells infected with
untreated virions, while p-EGCG had a much greater effect with a 99.5% reduction in
concentration of HSV-1’s US6 gene (Fig. 18). Thus, the concentration of HSV-1 DNA in
treated cells was significantly reduced in the presence of EGCG or p-EGCG (p < 0.05),
with p-EGCG showing the highest effect.
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Figure 17. Gel electrophoresis of PCR products. Top: PCR of HSV-1 glycoprotein D gene US6.
100 ng of DNA extracted from HSV-1/Vero cells was added to each PCR reaction. Middle: PCR
of HSV-1 GFP gene UL46. Bottom: PCR of HSV-1 VP11/12 tegument gene UL46. Lane 1:
HSV-1/Vero; Lane 2: 75 μM EGCG-HSV-1/Vero; Lane 3: 75 μM p-EGCG-HSV-1/Vero; Lane
4: Vero cells only; Lane 5: Negative control. “Reprinted from Food and Chemical Toxicology,
Volume 52, Aline de Oliveira, Sandra D. Adams, Lee H. Lee, Sean R. Murray, Stephen D. Hsu,
Jeffrey R. Hammond, Douglas Dickinson, Ping Chen, Tin-Chun Chu, Inhibition of herpes simplex
virus type 1 with the modified green tea polyphenol palmitoyl-epigallocatechin gallate, 207-215,
Copyright (2013), with permission from Elsevier, License number 3856720963132.”
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Figure 18. Relative percent concentration of US6 gene in EGCG-HSV-1/ Vero and p-EGCGHSV-1/Vero cells relative to control HSV-1/Vero cells based on qPCR. Percentage calculated
based on the relative expression with comparative Ct (n = 3). Y-error bars indicate SD.
“Reprinted from Food and Chemical Toxicology, Volume 52, Aline de Oliveira, Sandra D.
Adams, Lee H. Lee, Sean R. Murray, Stephen D. Hsu, Jeffrey R. Hammond, Douglas Dickinson,
Ping Chen, Tin-Chun Chu, Inhibition of herpes simplex virus type 1 with the modified green tea
polyphenol palmitoyl-epigallocatechin gallate, 207-215, Copyright (2013), with permission from
Elsevier, License number 3856720963132.”
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Binding assay suggests that 75 μM p-EGCG is capable of inhibiting HSV-1 Vero cell
attachment.
To determine if p-EGCG is able to inhibit the binding of HSV-1 to Vero cells, a
binding assay was carried out. This assay is performed at 4 °C, a temperature that allows
viral binding, but prevents viral penetration. Upon infecting the cells for 1 h, the unbound
virus is aspirated and cells washed with PBS. If p-EGCG is able to inhibit viral binding,
no infection will be observed. As seen in Fig. 19, p-EGCG is able to inhibit > 99% of
HSV-1 binding to host cell receptors. This suggests that p-EGCG is able to block viral
glycoprotein(s) and efficiently inhibit the infection cycle of HSV-1 (p < 0.05).
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Figure 19. Binding assay of HSV-1/Vero treated or untreated with 75 μM p-EGCG. The numbers
represent the mean of three trials and the y-error bars represent SD. “Reprinted from Food and
Chemical Toxicology, Volume 52, Aline de Oliveira, Sandra D. Adams, Lee H. Lee, Sean R.
Murray, Stephen D. Hsu, Jeffrey R. Hammond, Douglas Dickinson, Ping Chen, Tin-Chun Chu,
Inhibition of herpes simplex virus type 1 with the modified green tea polyphenol palmitoylepigallocatechin gallate, 207-215, Copyright (2013), with permission from Elsevier, License
number 3856720963132.”
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Plaque assay shows that 75 μM p-EGCG effectively inhibits HSV-2 plaque
formation in Vero cells
To determine the change in HSV-2 titer upon treatment with p-EGCG in Vero and
A549 cells, a plaque assay was performed. Similar to the results seen with HSV-1, pEGCG also effectively inhibits HSV-2 in Vero and A549 cells in a dose-dependent
manner (Fig. 20-22). While many plaques are seen in the control dish (Fig. 20B, 21B),
very few plaques are seen when HSV-2 is treated with 75 μM p-EGCG in both cell lines
(Fig. 20G, 21G). Remarkably, treating HSV-2 with 75 μM p-EGCG in Vero cells
decreased PFU/ml by 99.98 ± 0.02%, while in A549 cells, it decreased by 99.62 ±
0.002% (p < 0.05). Thus, the results suggest that p-EGCG may also be used effectively
in anti-HSV-2 treatments.
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Figure 20. Plaque assay of (A) Vero cells (B) HSV-2/Vero, (C) HSV-2 treated DMSO, (D) HSV-2 treated 12.5 μM
p-EGCG/Vero, (E) HSV-2 treated 25 μM p-EGCG/Vero, (F) HSV-2 treated 50 μM p-EGCG/Vero, (G) HSV-2
treated 75 μM p-EGCG/Vero.
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Figure 21. Plaque assay of (A) A549 cells (B) HSV-2/A549, (C) HSV-2 treated DMSO/A549, (D) HSV-2 treated 12.5 μM
p-EGCG/A549, (E) HSV-2 treated 25 μM p-EGCG/A549, (F) HSV-2 treated 50 μM p-EGCG/A549, (G) HSV-2 treated 75
μM p-EGCG/A549.
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Figure 22. Graph showing PFU of HSV-2/A549 treated with different concentrations of pEGCG. The numbers represent the mean of triplicate trials and the y-error bars represent SD.
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Fluorescence microscopy study demonstrates that 75 μM p-EGCG is effective in
inhibiting HSV-2/ GFP expression in Vero and A549 cells.
Fluorescence microscopy was also used to study HSV-2 life cycle in both Vero
and A549 cells. Since the HSV-2 used in the study contains a GFP tag, it was used to
analyze the possible p-EGCG effect in inhibiting HSV-2 GFP expression. As shown in
Fig. 23, GFP expression is exceptionally inhibited upon treatment with 75 μM p-EGCG
(Fig. 23D). While there are many green foci throughout the HSV-2 positive control in
both cell lines (Fig. 23 B, B’), the cells infected with 75 μM p-EGCG treated HSV-2
show close resemblance to the cells only negative control (Fig. 23 A, A’). This study
further confirms p-EGCG abilities to be used as an anti-HSV-2 agent.
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Figure 23. Fluorescent microscopy studies of Vero (A-D) and A549 (A’-D’) cells infected with
HSV-2 and treated with or without 75 μM p-EGCG. (A) Vero cells only, (A’) A549 cells only;
(B) HSV-2 positive control/Vero, (B’) HSV-2 positive control/A549; (C) HSV-2 treated with
DMSO/Vero, (C’) HSV-2 treated with DMSO/A549; (D) HSV-2 treated with 75 μM pEGCG/Vero, (D’) HSV-2 treated with 75 μM p-EGCG/A549.
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Flow cytometry study further demonstrates that EGCG and p-EGCG inhibit HSV-2
infection in Vero cells at a dose dependent manner
In order to further study the antiviral effect of EGCG and p-EGCG against HSV-2
in Vero cells, flow cytometric analyses were performed. Cells were infected with either
treated or untreated HSV-2 virus with various concentrations (6.25, 12.5, 25, 50, 75 μM)
of EGCG or p-EGCG. As previously seen with HSV-1, the antiviral effect of both EGCG
and p-EGCG is significantly different from HSV-2 control (p < 0.05). The HSV-2
inhibitory effect of both EGCG and p-EGCG is at a dose dependent manner, with pEGCG being more efficient (Fig. 24).
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Figure 24. Flow cytometric analysis of HSV-2 infection of Vero cells treated with different concentrations of EGCG amd
p-EGCG. (A) Vero cells only, (B) HSV-1 positive control, (C) HSV-1 treated with DMSO, (D-H) HSV-2 treated with
6.25, 12.5, 25, 50, 75 μM EGCG, (I-M) HSV-2 treated with 6.25, 12.5, 25, 50, 75 μM p-EGCG.
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Flow cytometry assay demonstrates that p-EGCG also inhibit HSV-2 infection in
A549 cells at a dose dependent manner
To further confirm the HSV-2 antiviral effect of p-EGCG seen in Vero cells, flow
cytometric analysis were also conducted in A549 cells. Cells were infected with either
treated or untreated HSV-2 virus with various concentrations (25, 50, 75 μM) of pEGCG. As seen in Fig. 25 and 26, the antiviral effect of p-EGCG in A549 cells is also at
a dose dependent manner and is significantly different from control (p < 0.05).
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Figure 25. Flow cytometric analysis of HSV-2 infection of A549 cells treated with different
concentrations of p-EGCG (A) A549 cells only, (B) HSV-2 positive control, (C) HSV-2 treated
with DMSO, (D-F) HSV-2 treated with 25, 50, 75 μM p-EGCG.
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Figure 26. Overlay of flow cytometric analysis of HSV-2 infection of A549 cells treated
with different concentrations of p-EGCG, HSV-2 positive control (red) HSV-2 treated
with DMSO (purple), HSV-2 treated with 25 μM p-EGCG (blue), 50 μM p-EGCG (dark
green), 75 μM p-EGCG (light green), A549 cells only (yellow).
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Cytopathic monitoring studies indicate that TF1, TF2, and TF3 with concentrations
up to 75 μM have no significant effect on Vero and A549 cell morphology.
Cytopathic studies were conducted to evaluate the effect of various concentrations
(6.25, 12.5, 25, 50, 75 μM) of TF1, TF2, and TF3 on Vero and A549 cells. As seen in
Fig. 27-29, no morphological abnormalities or cytotoxicity characteristics were observed
at any of the concentrations tested. Treatment of both cell lines with concentrations up to
75 μM of TF1, TF2, or TF3 (Fig. 27-29 B-D, B’-D’) showed similar cellular
morphologies to the cells that had not received any treatment (Fig. 27-29 A, A’).
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Figure 27. Cytopathic monitoring assay. Phase contrast microscopy of Vero and A549 cells
treated with different concentrations of Theaflavin 1. (A) Vero cells only, (A’) A549 cells only;
(B) DMSO treated Vero cells, (B’) DMSO treated A549 cells; (C) 12.5 μM TF1 treated Vero
cells, (C’) 12.5 μM TF1 treated A549 cells; (D) 25 μM TF1 treated Vero cells, (D’) 25 μM TF1
treated A549 cells; (E) 50 μM TF1 treated Vero cells, (E’) 50 μM TF1 treated A549 cells; (F) 75
μM TF1 treated Vero cells, (F’) 75 μM TF1 treated A459 cells.
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Figure 28. Cytopathic monitoring assay. Phase contrast microscopy of Vero and A549 cells
treated with different concentrations of Theaflavin 2. (A) Vero cells only, (A’) A549 cells only;
(B) DMSO treated Vero cells, (B’) DMSO treated A549 cells; (C) 12.5 μM TF2 treated Vero
cells, (C’) 12.5 μM TF2 treated A549 cells; (D) 25 μM TF2 treated Vero cells, (D’) 25 μM TF2
treated A549 cells; (E) 50 μM TF2 treated Vero cells, (E’) 50 μM TF2 treated A549 cells; (F) 75
μM TF2 treated Vero cells, (F’) 75 μM TF2 treated A459 cells.

67

A

A’

B

B’

C

C’

D

D’

E

E’

F

F’

Figure 29. Cytopathic monitoring assay. Phase contrast microscopy of Vero and A549 cells
treated with different concentrations of Theaflavin 1. (A) Vero cells only, (A’) A549 cells only;
(B) DMSO treated Vero cells, (B’) DMSO treated A549 cells; (C) 12.5 μM TF3 treated Vero
cells, (C’) 12.5 μM TF3 treated A549 cells; (D) 25 μM TF3 treated Vero cells, (D’) 25 μM TF3
treated A549 cells; (E) 50 μM TF3 treated Vero cells, (E’) 50 μM TF3 treated A549 cells; (F) 75
μM TF3 treated Vero cells, (F’) 75 μM TF3 treated A459 cells.
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Cell proliferation assay (MTS) shows that TF1, TF2, and TF3 with concentrations
up to 75 μM have no significant effect on Vero and A549 cell proliferation.
Vero and A549 cells were exposed to different concentrations (12.5, 25, 50, 75
μM) of TF1, TF2, and TF3 for 1 h and then observed for possible cytotoxic and or
proliferation effects 24 h later. As seen in Figure 30, theaflavin treatments with
concentrations up to 75 μM showed no significant effect on Vero and A549 cell
proliferation compared to untreated controls. The percent cell proliferation was assessed
based on the OD490nm for triplicate tests for each theaflavin. Results for 12.5, 25, 50, and
75 μM TF1 in Vero cells include 89.99 ± 2.48%, 93.77 ± 6.52%, 90.29 ± 3.79%; 87.39 ±
8.87% respectively. Results for 12.5, 25, 50, and 75 μM TF1 in A549 cells include 99.20
± 2.18%; 100 ± 2.91%; 98.14 ± 5.04%; 98.73 ± 1.08% respectively. Results for 12.5, 25,
50, and 75 μM TF2 in Vero cells include 86.20 ± 0.81%; 87.90 ± 3.81%; 98.73 ±
10.04%; 93.16 ± 6.86% respectively. Results for 12.5, 25, 50, and 75 μM TF2 in A549
cells include 98.17 ± 5.30%; 100 ± 3.39%; 99.99 ± 4.20%; 100 ± 2.03% respectively.
Results for 12.5, 25, 50, and 75 μM TF3 in Vero cells include 100 ± 5.42%; 95.69 ±
2.68%; 98.03 ± 4.39%; 100 ± 4.74% respectively. Results for 12.5, 25, 50, and 75 μM
TF3 in A549 cells 100 ± 2.23%; 100 ± 1.86%; 100 ± 3.19%; 100 ± 6.34% respectively.
As seen, concentrations of TF1, TF2 and TF3 up to 75 μM are not significantly different
from control (p = 0.3952), and do not affect cell proliferation. Thus, Vero and A549 cells
exposed to high concentrations of TF1, TF2, and TF3 are competent for cell proliferation,
suggesting that these compounds are not toxic to Vero and A549 cells and can be used to
further investigate their inhibitory effect against HSV-1 and HSV-2.
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Figure 30. Cell viability and proliferation studies of Vero and A549 cells treated with different
concentrations (0, 12.5, 25, 50 and 75 μM) of TF1, TF2, and TF3 using MTS assay. The means of
results of triplicate tests of Vero cells samples (striped) and A549 cells samples (solid) represent
the average of triplicate trials. The y-error bars represent SD. “Reprinted from Antiviral Research,
Volume 118, Aline de Oliveira, Derek Prince, Chih-Yu Lo, Lee H. Lee, Tin-Chun Chu, Antiviral
activity of theaflavin digallate against herpes simplex virus type 1, 56-67, Copyright (2015), with
permission from Elsevier, License number 3856721491636.”
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Plaque assay shows that TF3 is more effective in reducing HSV-1 plaque formation
in Vero and A549 cells compared to TF1 and TF2.
In order to study the effect of each theaflavin’s ability to inhibit HSV-1 plaque
formation in Vero and A549 cells, a plaque assay was performed. As seen in Fig. 31 and
32, plaque formation is significantly different in treated HSV-1 compared to control (p <
0.05), and inhibition is seen at a dose dependent manner for all three theaflavins tested.
Exposing HSV-1 to 25 and 50 μM TF1 caused a 29.2 ± 5.8% and 77.2 ± 0.78% HSV-1
PFU reduction respectively in Vero cells and 12.84 ± 4.02% and 89.85 ± 1.12%
respectively in A549 cells. Exposure to 25 μM and 50 μM TF2 caused a 20.3 ± 0.45%
and 89 ± 1.5% reduction in HSV-1 PFU respectively in Vero and 13.88 ± 2.99% and 99.3
± 0.01% respectively in A549 cells. Exposure of 25 μM and 50 μM TF3 caused a 86.9 ±
0.44% decrease in HSV-1 PFU respectively in Vero cells and 93.56 ± 0.32% and >99%
decrease respectively in A549 cells. As seen, although TF1, TF2 and TF3 all work
remarkably well in inhibiting the formation of HSV-1 plaques, TF3 is the most effective
in both cell lines.
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Figure 31. Plaque Assay of HSV-1 infection of Vero cells treated with different concentrations
(0, 25, 50 and 75 μM) of TF1 TF2 and TF3. (A) Vero cells only, (B) HSV-1 positive control, (C)
HSV-1 treated with DMSO, (D-F) 25, 50 and 75 μM TF1 (G-I) 25, 50 and 75 μM TF2; (J-L) 25,
50 and 75 μM TF3. “Reprinted from Antiviral Research, Volume 118, Aline de Oliveira, Derek
Prince, Chih-Yu Lo, Lee H. Lee, Tin-Chun Chu, Antiviral activity of theaflavin digallate against
herpes simplex virus type 1, 56-67, Copyright (2015), with permission from Elsevier, License
number 3856721491636.”
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Figure 32. PFU of HSV-1 treated with different concentrations (0, 12.5, 25, 50 and 75 μM) of
TF1, TF2 and TF3 in Vero and A549 cells. The numbers represent the mean of triplicate trials
and the y-error bars represent SD. “Reprinted from Antiviral Research, Volume 118, Aline de
Oliveira, Derek Prince, Chih-Yu Lo, Lee H. Lee, Tin-Chun Chu, Antiviral activity of theaflavin
digallate against herpes simplex virus type 1, 56-67, Copyright (2015), with permission from
Elsevier, License number 3856721491636.”
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Flow cytometry study further demonstrates that TF1, TF2, and TF3 inhibit HSV-1
infection in Vero and A549 cells at a dose dependent manner.
In order to further study the antiviral effect of TF1, TF2, and TF3 against HSV-1
in Vero and A549 cells, flow cytometric analyses were performed. Cells were infected
with either treated or untreated HSV-1 virus with various concentrations (25, 50, 75 μM)
of TF1 in Vero cells (D-F), A549 cells (D’-F’), TF2 in Vero cells (G-I), A549 cells (G’I’), and TF3 in Vero cells (J-L), A549 cells (J’-L’). As seen in Figs. 33, and 34, the
antiviral effect of TF1, TF2, and TF3 is at a dose dependent manner. Although all three
theaflavins work well in reducing HSV-1 infection in both Vero and A549 cells, 50 μM
and above TF3 significantly inhibits (> 99%) HSV-1 GFP expression (p < 0.05) (Fig. 3336).
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Figure 33. Flow cytometric analysis of HSV-1 infection of Vero cells treated with different
concentrations of TF1, TF2, and TF3. (A) Vero cells only, (B) HSV-1 positive control, (C) HSV1 treated with DMSO, (D-F) HSV-1 treated with 25, 50, 75 μM TF1, (G-I) HSV-1 treated with
25, 50, 75 μM TF2, (J-L) HSV-1 treated with 25, 50, 75 μM TF3. “Reprinted from Antiviral
Research, Volume 118, Aline de Oliveira, Derek Prince, Chih-Yu Lo, Lee H. Lee, Tin-Chun Chu,
Antiviral activity of theaflavin digallate against herpes simplex virus type 1, 56-67, Copyright
(2015), with permission from Elsevier, License number 3856721491636.
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Figure 34. Flow cytometric analysis of HSV-1 infection of A549 cells treated with different
concentrations of TF1, TF2, and TF3. (A) Vero cells only, (B) HSV-1 positive control, (C) HSV1 treated with DMSO, (D-F) HSV-1 treated with 25, 50, 75 μM TF1, (G-I) HSV-1 treated with
25, 50, 75 μM TF2, (J-L) HSV-1 treated with 25, 50, 75 μM TF3. “Reprinted from Antiviral
Research, Volume 118, Aline de Oliveira, Derek Prince, Chih-Yu Lo, Lee H. Lee, Tin-Chun Chu,
Antiviral activity of theaflavin digallate against herpes simplex virus type 1, 56-67, Copyright
(2015), with permission from Elsevier, License number 3856721491636.”
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Figure 35. Histogram overlay (A) or offset (B) of the antiviral effect of TF1, TF2, and TF3
against HSV-1 infected A549 cells as analyzed by flow cytometric system. The histograms depict
GFP Intensity from the GHSV-UL46 strain of HSV-1 in (A) A549 cells only (yellow), 50 μM
TF3 treated HSV-1/A549 (orange), 75 μM TF3 treated HSV-1/A549 (green), HSV-1
control/A549 (red), HSV-1/DMSO control/A549 (purple).
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Figure 36. Percentage of positively infected A549 cells based on GFP intensity. (Green) HSV-1
exposed to 0, 25, 50, and 75 μM of TF1; (Orange) HSV-1 exposed to 0, 25, 50, and 75 μM of
TF2; (Blue) HSV-1 exposed to 0, 25, 50, and 75 μM of TF3.
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Fluorescence microscopy demonstrates that 75 μM TF3 is effective in inhibiting
HSV-1/GFP expression in Vero and A549 cells.

Fluorescence microscopy was also used to study HSV-1 life cycle when treated
with 75 μM TF3 in both Vero and A549 cells. Since the HSV-1 used in this study
contains a GFP tag, it was used to study the possible effect of TF1, TF2 and TF3 to
inhibit GFP expression upon viral infection. As shown in Fig. 37, GFP expression is
greatly inhibited upon treatment with 75 μM TF3. While there are many green foci
throughout the HSV-1 positive control (Fig. 37 B, B’), the cells infected with 75 μM TF3
treated HSV-1 shows close resemblance to the cells only negative control (Fig. 37 A, A’).
This assay further confirms TF3’s potential to serve as an anti-HSV-1 agent.
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Figure 37. Fluorescent microscopy studies of Vero (A-D) and A549 (A’-D’) cells treated with or
without 75 μM TF3. (A) Vero cells only, (A’) A549 cells only; (B) HSV-1 positive control/Vero,
(B’) HSV-1 positive control/A549; (C) HSV-1 treated with DMSO/Vero, (B’) HSV-1 treated
with DMSO/A549; (D) HSV-1 treated with 75 μM TF3/Vero, (D’) HSV-1 treated with 75 μM
TF3/A549. “Reprinted from Antiviral Research, Volume 118, Aline de Oliveira, Derek Prince,
Chih-Yu Lo, Lee H. Lee, Tin-Chun Chu, Antiviral activity of theaflavin digallate against herpes
simplex virus type 1, 56-67, Copyright (2015), with permission from Elsevier, License number
3856721491636.”
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Binding assay suggest that 75 μM TF3 is capable of inhibiting HSV-1 host cell
attachment in Vero and A549 cells.
To determine whether TF3 inhibits HSV-1 from binding and attaching to Vero
and A549 host cell receptors, a binding assay was performed. The viral infection is done
at 4 °C, a temperature that allows viral binding but prevents viral penetration. Upon viral
attachment to host cells receptors, the cells are washed with PBS and the cells are then
placed back at 37 °C. If TF3 disrupts viral attachment, upon washing the cells with PBS,
little to no viruses should be left in the plate and thus no infection will occur. As seen in
Fig. 38 and 39, while many plaques were seen in the HSV-1 positive control dish, no
plaques are seen when HSV-1 is treated with 50 μM and 75 μM TF3. Binding of HSV-1
treated with 50 μM and 75 μM TF3 to host cells were significantly different compared to
control HSV-1 (p < 0.05). This assay suggests that TF3 works directly at the point of
viral attachment preventing the virus from penetrating and continuing its life cycle.
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Figure 38. Binding assay of HSV-1 infection of Vero cells treated with or without different concentrations (0, 50 and 75 μM) of TF3. (A)
Vero cells only, (B) HSV-1 positive control, (C) HSV-1 positive treated with DMSO, (D) HSV-1 treated with 50 μM TF3, (E) HSV-1
treated with 75 μM.
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Figure 39. Binding assay of HSV-1 infection of Vero and A549 cells treated with or without
different concentrations (0, 50 and 75 μM) of TF3. The means of results of triplicate tests of Vero
cells samples (striped) and A549 cells samples (solid) represent the average of triplicate trials.
The y-error bars represent SD. “Reprinted from Antiviral Research, Volume 118, Aline de
Oliveira, Derek Prince, Chih-Yu Lo, Lee H. Lee, Tin-Chun Chu, Antiviral activity of theaflavin
digallate against herpes simplex virus type 1, 56-67, Copyright (2015), with permission from
Elsevier, License number 3856721491636.”
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Penetration assay suggest that 75 μM TF3 is capable of inhibiting HSV-1 host cell
penetration.
To determine whether TF3 inhibits HSV-1 from penetrating Vero and A549 host
cell, a penetration assay was performed. The virus is allowed to bind to the cells at 4 °C
and then the treatment is added to the cells and placed at 37 °C. If TF3 disrupts viral
penetration, HSV-1 virions would not be able to penetrate the cells, and no plaques would
form. As seen in Fig. 40 and 41, while many plaques were seen in the HSV-1 positive
control dish, very few plaques are seen when HSV-1 is treated with 50 μM TF3 (a
decrease of 84.28 ± 5.28% and 58.05 ± 12.01% in Vero and A549 cells accordingly) and
no plaques are seen when HSV-1 is treated with 75 μM TF3 (> 99% decrease). The PFU
were significantly different from control (p < 0.05). This assay suggests that TF3 also
works at the point of viral penetration, preventing the virus from continue the course of
its life cycle in both Vero and A549 cells.
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Figure 40. Penetration assay of HSV-1 infection of Vero cells treated with or without different concentrations (0, 50 and
75 μM) of TF3. (A) Vero cells only, (B) HSV-1 positive control, (C) HSV-1 positive treated with DMSO, (D) HSV-1
treated with 50 μM TF3, (E) HSV-1 treated with 75 μM.
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Figure 41. Penetration assay of HSV-1 infection of Vero and A549 cells treated with or without different concentrations
(0, 50 and 75 μM) of TF3. The means of results of triplicate tests of Vero cells samples (striped) and A549 cells samples
(solid) represent the average of triplicate trials. The y-error bars represent SD. “Reprinted from Antiviral Research,
Volume 118, Aline de Oliveira, Derek Prince, Chih-Yu Lo, Lee H. Lee, Tin-Chun Chu, Antiviral activity of theaflavin
digallate against herpes simplex virus type 1, 56-67, Copyright (2015), with permission from Elsevier, License number
3856721491636.”
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Flow cytometry assay confirms TF3 ability to inhibit host cell receptor binding and
penetration in Vero and A549 cells.
To further determine at what point of HSV-1 viral infection TF3 works, a flow
cytometry assay was conducted. Treatment with 75 μM TF3 of either cell only or HSV-1
virions were performed at different time points during infection. As seen in Fig. 42a and
42b, when cells were pre-treated with 75 μM TF3 prior to infection (Fig. 42 E and E’)
viral infection still occurred when compared to HSV-1 positive control (Fig. 42 B, B’).
Cells were also greatly infected when cells were treated at 2, 4, 6, 8, and 10 h post
infection (Fig. 42 H-L, H’L’). On the contrary, viral infection is inhibited when HSV-1 is
pre-treated with 75 μM TF3 prior to infection or when treated at the same of infection (0
h) in both Vero and A549 (Fig. 42 F, G and F’G’). The percentage of HSV-1 GFP
expression seen in treated HSV-1 infected cells is significantly different from the control
(p < 0.05). This assay suggests that TF3 acts at the point of viral binding and penetration
to host cells and not after the virus has already entered the cells.
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Figure 42. Flow cytometric analysis of Vero (a) and A549 (b) cells treated with 75 μM of TF3 at
different time points during the HSV-1 viral life cycle. (A) Vero cells only; (A’) A549 cells only
(B) HSV-1 positive control/Vero; (B’) HSV-1 positive control/ A549 (C) HSV-1 treated with
DMSO at 2 h/ Vero; (C’) HSV-1 treated with DMSO at 2 h/ A549 (D) HSV-1 treated with
DMSO at 10 h/Vero; (D’) HSV-1 treated with DMSO at 10 h/A549; (E) Vero cells treated with
75 μM of TF3 prior to HSV-1 infection; (E’) A549 cells treated with 75 μM of TF3 prior to HSV1 infection; (F) HSV-1 treated with 75 μM of TF3 prior to infection/Vero; (F’) HSV-1 treated
with 75 μM of TF3 prior to infection/A549; (G) HSV-1 treated with 75 μM of TF3 at 0 h ; (G’)
HSV-1 treated with 75 μM of TF3 at 0 h/ A549 (H) HSV-1 treated with 75 μM of TF3 at 2
h/Vero; (H’) HSV-1 treated with 75 μM of TF3 at 2 h/A549 (I) HSV-1 treated with 75 μM of TF3
at 4 h/Vero (I’) HSV-1 treated with 75 μM of TF3 at 4 h /A549 (J) HSV-1 treated with 75 μM of
TF3 at 6 h/Vero; (J’) HSV-1 treated with 75 μM of TF3 at 6 h/A549; (K) HSV-1 treated with 75
μM of TF3 at 8 h/Vero; (K’) HSV-1 treated with 75 μM of TF3 at 8 h/A549 (L) HSV-1 treated
with 75 μM of TF3 at 10 h/Vero; (L’) HSV-1 treated with 75 μM of TF3 at 10 h/A549.
“Reprinted from Antiviral Research, Volume 118, Aline de Oliveira, Derek Prince, Chih-Yu Lo,
Lee H. Lee, Tin-Chun Chu, Antiviral activity of theaflavin digallate against herpes simplex virus
type 1, 56-67, Copyright (2015), with permission from Elsevier, License number
3856721491636.”
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Plaque assay shows that TF3 is more effective in reducing HSV-2 plaque formation
in Vero and A549 cells compared to TF1 and TF2.
In order to study the effect of each theaflavin on HSV-2’s ability to inhibit plaque
formation in Vero and A549 cells, a plaque assay was performed. Cells were infected
with different concentrations (25, 50, 75 µM) of TF1, TF2, or TF3 for 1 h and plaques
were visualized 50 h post infection. As seen in Fig. 43-45, plaque formation was
inhibited at a dose dependent manner for all three theaflavins tested when compared to
the HSV-2 positive control. Exposing HSV-2 to 25 µM TF1 caused a 98.0 ± 0.20% and
66.0 ± 1.92% HSV-2 PFU reduction in Vero and A549 cells respectively. Exposure to 25
µM TF2 caused a 99.0 ± 0.06% and 70.0 ± 1.9% HSV-2 PFU reduction in Vero and
A549 cells respectively. Exposure of 25 µM TF3 caused a 99.7 ± 0.05% and 98.0 ±
0.048% HSV-2 PFU reduction in Vero and A549 cells respectively. Remarkably, 50 µM
and above TF1, TF2, and TF3 was sufficient to significantly inhibit > 99% (p < 0.05)
plaque formation in both Vero and A549 cells. As seen previously with the results
obtained for HSV-1, TF3 also shows to be the most effective in inhibiting HSV-2 plaque
formation in Vero and A549 cells.
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Figure 43. Plaque Assay of HSV-2 infection of Vero cells treated with different concentrations
(0, 25, 50 and 75 µM) of TF1 TF2 and TF3. (A) Vero cells only, (B) HSV-2 positive control, (C)
HSV-2 treated with DMSO, (D-F) 25, 50 and 75 µM TF1 (G-I) 25, 50 and 75 µM TF2; (J-L) 25,
50 and 75 µM TF3.
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Figure 44. Plaque Assay of HSV-2 infection of A549 cells treated with different concentrations
(0, 25, 50 and 75 µM) of TF1 TF2 and TF3. (A) A549 cells only, (B) HSV-2 positive control, (C)
HSV-2 treated with DMSO, (D-F) 25, 50 and 75 µM TF1 (G-I) 25, 50 and 75 µM TF2; (J-L) 25,
50 and 75 µM TF3.
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Flow cytometry study indicate that TF3 inhibits HSV-2 GFP expression in a
concentration dependent manner.
Flow cytometric analysis was utilized to further assess black tea theaflavins’
ability to inhibit HSV-2 infection in Vero and A549 cells. HSV-2 was treated with
different concentrations (0, 6.25, 12.5, 25, 50 and 75 μM) of TF1, TF2, and TF3. While
6.25 μM of TF1, TF2 or TF3 show no significant HSV-2 inhibiting effect, a low
concentration of 12.5 μM TF3 is sufficient to significantly repress HSV-2 GFP viral
expression (p < 0.05). As seen in Fig. 46, while a high HSV-2 GFP viral expression is
still seen at treatments of 12.5 μM TF1 (85.6%) and 12.5 μM TF2 (48.9%), when HSV-2
is treated with 12.5 μM TF3, there is a HSV-2 GFP expression of only 26.5% GFP in
Vero cells. Remarkably, 25 μM and above TF1, TF2, and TF3 is sufficient to
significantly inhibit (p < 0.05) HSV-2 GFP expression in both cell lines (Fig. 46, 47).
Overall, the results observed with HSV-2 infection resemble the results previously seen
with HSV-1 infection in Vero and A549 cells. While all three theaflavins are effective in
inhibiting the HSV-2 in both cell lines, TF3 seems to be the most effective.
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Figure 46. Flow cytometric analysis of HSV-2 infection of Vero cells treated with different
concentrations of TF1, TF2, and TF3. (A) Vero cells only, (B) HSV-2 positive control, (C) HSV2 treated with DMSO, (D-H) HSV-2 treated with 6.25, 12.5 25, 50, 75 μM TF1, (I-M) HSV-2
treated with 6.25, 12.5 25, 50, 75 μM TF2, (N-R) HSV-2 treated with 6.25, 12.5, 25, 50, 75 μM
TF3.
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Figure 47. Flow cytometric analysis of HSV-2 infection of A549 cells treated with different
concentrations of TF1, TF2, and TF3. (A) Vero cells only, (B) HSV-2 positive control, (C) HSV2 treated with DMSO, (D-F) HSV-2 treated with 25, 50, 75 μM TF1, (G-I) HSV-2 treated with
25, 50, 75 μM TF2, (J-L) HSV-2 treated with 25, 50, 75 μM TF3.
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Fluorescence microscopy demonstrates that 75 μM TF3 is effective in inhibiting
HSV-2/GFP expression in Vero and A549 cells.
Fluorescence microscopy was used to study HSV-2 life cycle in both Vero and
A549 cells. Since the HSV-2 used in this study has a GFP tag, it was used to identify the
possible effect of TF1, TF2 and TF3 to inhibit GFP expression upon viral infection. As
shown in Fig. 48, GFP expression is inhibited upon treatment with 75 μM TF3. While
there are many green foci throughout the HSV-2 positive control (Fig. 48 B, B’), the cells
infected with 75 μM TF3 treated HSV-2 (Fig. 48 D, D’) share close resemblance to the
‘cells only’ negative control (Fig. 48 A, A’). This assay further confirms TF3’s ability of
inhibiting HSV-2 infection in Vero and A549 cells.
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Figure 48. Fluorescent microscopy studies of Vero (A-D) and A549 (A’-D’) cells treated with or
without 75 μM TF3. (A) Vero cells only, (A’) A549 cells only; (B) HSV-2 positive control/Vero,
(B’) HSV-2 positive control/A549; (C) HSV-2 treated with DMSO/Vero, (B’) HSV-2 treated
with DMSO/A549; (D) HSV-2 treated with 75 μM TF3/Vero, (D’) HSV-2 treated with 75 μM
TF3/A549.
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Quantitative PCR (qPCR) analysis further confirms TF1, TF2, and TF3 ability to
inhibit HSV-2 in both Vero and A549 cells, with TF3 being the most efficient.
qPCR analysis was conducted to further analyze the effect of TF1, TF2, and TF3
in inhibiting HSV-2 infection in both Vero and A549 cells. As seen in Fig. 49 and 50, all
three black tea theaflavins significantly inhibit HSV-2 infection in both cell lines, in a
dose dependent manner (p < 0.05). As concentrations of theaflavins increased, the
expression of US6 gene decreased. Remarkably, 12.5 μM and above TF1, TF2, TF3
inhibits > 99% expression of US6 gene. Similar to the results previously seen with HSV1, TF3 seems to also be more effective in inhibiting HSV-2 compared to TF1 and TF2.
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Figure 49. Quantitative PCR (qPCR) analysis of US6 gene expression (glycoprotein D) of HSV2 in Vero cells.
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Figure 50. Quantitative PCR (qPCR) analysis of US6 gene expression (glycoprotein D) of HSV2 in A549 cells.
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Flow cytometry assay also confirms TF3 ability to inhibit host cell receptor binding
and penetration of HSV-2.
Flow cytometric analysis was conducted to observe at what stage of HSV-2 life
cycle TF3 affects. As seen in Fig. 51, no significant anti-HSV-2 effect was seen when the
cells were pre-treated prior to infection (Fig. 51E), nor when cells were treated with 75
μM TF3 post infection (Fig. 51 H-L). Significant HSV-2 inhibition is only seen when the
virus is pre-treated with 75 μM TF3 prior to infection (Fig. 51F) or at the time of
infection (0 h) (Fig. 51G) (p < 0.05). Thus, as seen previously with the studies done with
HSV-1 infection, TF3 also seems to be acting at the binding/ penetration step of the
HSV-2 viral life cycle.
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Figure 51. Flow cytometric analysis of Vero cells treated with 75 μM of TF3 at different time
points during the HSV-2 viral lifecycle. (A) Vero cells only; (B) HSV-2 positive control; (C)
HSV-2 treated with DMSO at 2 h; (D) HSV-2 treated with DMSO at 10 h; (E) Vero cells treated
with 75 μM of TF3 prior to HSV-2 infection; (F) HSV-2 treated with 75 μM of TF3 prior to
infection; (G) HSV-2 treated with 75 μM of TF3 at 0 h; (H) HSV-2 treated with 75 μM of TF3 at
2 h; (I) HSV-2 treated with 75 μM of TF3 at 4 h (J) HSV-2 treated with 75 μM of TF3 at 6 h; (K)
HSV-2 treated with 75 μM of TF3 at 8 h; (L) HSV-2 treated with 75 μM of TF3 at 10 h.
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Scanning electron microscopy (SEM) further confirms TF3’s ability to inhibit HSV2 in Vero cells.
SEM observations of Vero cells infected with 75 μM TF3 treated or untreated
HSV-2 further confirms TF3’s remarkable ability to inhibit HSV infection. As seen in
Fig. 52, when cells are infected with HSV-2 for 24 h, many viral particles are see on the
surface of the cell, and the cell morphology resembles that of an infected cell. Contrarily,
treating HSV-2 with 75 μM TF3, stops the virus from binding and penetrating the cells,
and thus no sign of infection is seen (Fig. 52B). 75 μM TF3 treated cells resemble the
negative control cells (Fig. 52C).
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Figure 52. Scanning Electron analysis of Vero cells infected with HSV-2 (A) of Vero cells
infected with 75 μM TF3 treated HSV-2 (B), and Vero cells only (C).
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Discussion
HSV-1 and HSV-2 infections affect millions of people worldwide. While there is
no cure for the diseases caused by HSV infections, efforts have been made to obtain
antiviral therapies capable of blocking viral infectivity. Although researchers have been
in a constant strive to identify an effective HSV vaccine, to date, there has been little to
no success. Currently, patients affected by HSV infections are mostly treated with
nucleoside analogues. While nucleoside analogues are effective in inhibiting HSV
infections by targeting the viral DNA polymerase and blocking DNA synthesis, resistant
strains have been observed. Thus, with the rise of drug resistant viruses, there is a need
to develop new antiviral therapies.
The goal of this project was to identify and study natural tea polyphenol agents as
novel, effective and safe antiviral drug candidates capable of entering human clinical
trials in the near future. In order to accomplish this goal, we first evaluated the effect of
green tea polyphenols EGCG, and its modified version, p-EGCG, on HSV-infected Vero
cells. Results of cell viability and cell proliferation assays indicate that p-EGCG is not
toxic to cultured Vero cells and show that modification of the green tea polyphenol
EGCG with palmitate increases the effectiveness of EGCG as an antiviral agent.
Furthermore, p-EGCG is a more potent inhibitor of HSV-1 than EGCG alone and can be
topically applied to skin, one of the primary tissues infected by HSV-1. Plaque forming
assay, viral binding assay, PCR, real-time PCR, and fluorescence microscopy were used
to demonstrate that p-EGCG concentrations of 50 μM and higher block the production of
infectious HSV-1 particles. Next, since HSV-1 and HSV-2 have very similar genomes,
we tested to see if similar effects would be observed in HSV-2 infected Vero and A549
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cells. Results of A549 cellular cytotoxicity indicated that EGCG and p-EGCG are not
toxic to cells up to 75 μM concentrations. Plaque forming assay, fluorescence microscopy
and flow cytometry assay, also confirmed p-EGCG’s effectiveness against HSV-2 in both
cell lines. As seen previously with HSV-1, concentrations of 50 μM and higher p-EGCG
were also able to effectively inhibit HSV-2 viral life cycle. Since p-EGCG was found to
inhibit HSV adsorption to cells, it may provide a novel treatment for HSV infections.
We then evaluated the effect of black tea theaflavins TF1, TF2, and TF3 on HSV1 and HSV-2 infected Vero and A549 cells. Results of Vero and A549 cellular
cytotoxicity indicated that TF1, TF2, and TF3 are not toxic to either cell lines up to 75
μM concentrations. Plaque forming assays, fluorescence microscopy, real time PCR, and
flow cytometry assays also showed that all three theaflavins are highly efficacious in
inhibiting HSV-1 and HSV-2 infection in Vero and A549 cells, with TF3 being the most
efficient. Studies done using flow cytometry, binding and penetration assays to
investigate the mode of action of TF3 in inhibiting HSV-1 and HSV-2, suggest that black
tea theaflavins also act at the adsorption/ penetration point of infection. By effectively
inhibiting the virus from entering the cells black tea theaflavins is able to prevent
infection (Fig. 53).
Furthermore, by using recombinant viruses containing a GFP tag, GHSV-UL46
(HSV-1) and HSV2-VP26-GFP (HSV-2), we were able to fully study the HSV viral life
cycle through the usage of flow cytometry (488 nm blue laser) and fluorescence
microscopy assays.
Finally, natural compounds may be a great way of obtaining antiviral products,
while minimizing toxicity and side effects. Green tea polyphenols and black tea
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theaflavins have previously been shown to contain many pharmacological activities,
including antibacterial and antiviral effects. Here, we show that both green tea
polyphenols and black tea theaflavins are extremely effective in inhibiting HSV-1 and
HSV-2 infections, and may serve as the main ingredient in a natural treatment or an
enhancer to currently marketed therapies.
Overall, this study successfully identified, and analyzed the effect of EGCG, pEGCG, TF1, TF2 and TF3 on the infection cycle of HSV-1 and HSV-2 in two different
mammalian cell lines, Vero and A549. The results acquired in this study should serve to
provide both the research and healthcare communities with future safe antiviral solutions
to the current HSV viral resistance problem.
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Figure 53. Proposed mechanism of p-EGCG and TF3. HSV-1 and HSV-2 are directly inhibited at
the binding/ adsorption step of the viral life cycle. Unable to bind to the host cell receptors, the
virus does not enter the cell and in turn cannot make new virions.
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